PDL BioPharma, Inc.
PDL BioPharma Announces New Licensing Agreement With Eli Lilly
Published in Law and Health Weekly, January 9th, 2010
PDL BioPharma, Inc. (NASDAQ:PDLI) announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company (NYSE:LLY) under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules. Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus. No other details of the licensing agreement were made available.
Lilly currently holds a license to the Queen et al patents with respect to solanezumab, its humanized antibody to beta amyloid which is currently being...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- AARP Idaho
AARP Idaho Applauds Senate for Moving Health Care Reform Forward - AARP Idaho
Health Care Reform Moves One Step Closer to Bringing Relief to Idaho Families - AARP Maryland
AARP Maryland Applauds Senate for Moving Health Care Reform Forward - AARP Pennsylvania
AARP Thanks Senate for Passing Health Care Reform - Acacia Research Corporation
Acacia Subsidiary Licenses Medical Picture Archiving and Communication System PACS Technology to Aspyra - AdMeTech Foundation
Congress Approves Defense Spending Bill Containing $1.6 Million for Pioneering Research to Improve Prostate Cancer Imaging - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
